Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pursuing Productive Pharma Partnerships In Korea

Executive Summary

Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.

You may also be interested in...

MSD Accesses Korea Oncology Innovation Through State Fund

In an ongoing series of joint R&D programs with big foreign pharma firms, the Korea Drug Development Fund has tied up with MSD to support the development of novel cancer therapies.

Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal

Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.

D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s

After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts